NybergSNakashimaYNordstromALHalldinCFardeL. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs: Review of D2 and 5HT2 receptor occupancy studies and clinical response. Br J Psychiatry1996;168(suppl 29):40–4.
2.
ChouinardGJonesBRemingtonGBloomDAddingtonDMacEwanGWA Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol1993;13:25–40. Erratum 1993;13:149.
3.
Diagnostic and statistical manual of mental disorders. 4th ed.Washington, DC: American Psychiatric Association, 1994.
4.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEAA method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239–45.
5.
VercueilLFoucherJ. Risperidone-induced tardive dystonia and psychosis (letter). Lancet1999;353:981.
6.
FdhilHKrebsMOBayleFVanelleJMOlieJP. Risperidone-induced tardive dystonia: A case of torticollis. Encephale1998;24:581–3.
7.
SherrJDThakerG. Progression of abnormal involuntary movements during risperidone treatment. J Clin Psychiatry1998;59:478–9.
